2024-03-25 14:08:26 ET
Summary
- Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations, and the new CEO's turnaround plan looks promising.
- Teva is an Israeli pharmaceutical company focused on affordable generic medicine, with a strong presence in North America.
- The company has consistent profitability, with a 50% gross margin and 20% operating margin, and plans to deleverage and diversify its product offerings.
My thesis
Read the full article on Seeking Alpha
For further details see:
Teva Pharmaceutical Industries: Potential Outweighs Concerns